CERO — CERo Therapeutics Holdings Share News
0.000.00%
Last trade - 00:00Brief: Cero Therapeutics Provides Clinical Update On Phase 1 Trial Of Cer-1236 In Aml (Certaint-1)
Brief: Cero Therapeutics Provides Clinical Update On Phase 1 Trial Of Cer-1236 In Aml
Brief: Cero Therapeutics Provides Clinical Update On Phase 1 Clinical Trial
Brief: Cero Therapeutics Holdings Inc - Continues To Evaluate Additional Options For Up-List
Brief: CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML
U.S. STOCKS ON THE MOVE-Keurig Dr Pepper, Ardelyx, Vertiv
U.S. STOCKS ON THE MOVE-Broadcom, JPMorgan, Enpro
CERo climbs after blood cancer drug trial moves to next phase
Brief: CERo Therapeutics Announces Completion Of First Cohort Of Phase 1 Clinical Trial Of Cer-1236 In Aml
Brief: CERo Therapeutics Advances Phase 1 CER-1236 Trial with Dose Intensification in AML
U.S. STOCKS ON THE MOVE-Broadcom, copper miners, MarketAxess
U.S. STOCKS ON THE MOVE-US homebuilders, Broadcom, Copper miners
Brief: Cero Therapeutics Receives FDA Fast Track Designation For Cer-1236 In Acute Myeloid Leukemia (Aml)
U.S. STOCKS ON THE MOVE-Guidewire, CERo Therapeutics, BioNTech
CERo Therapeutics jumps on US FDA's 'fast track' tag for cancer therapy
Brief: CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient With Cer-1236
Brief: CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236
Brief: Cero Therapeutics Holdings Inc - Receives Nasdaq Notice For Bid Price Non-Compliance
Brief: CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial